Interferon-α treatment in systemic mastocytosis

Current Drug Targets

Volumn 12, Issue 3, 2011, Pages 433-436

  Bjerrum, Ole Weis ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Classification; Interferon; Mast cells; Mastocytosis; Review; Treatment

Indexed keywords

ADRENALIN; ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CLADRIBINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; PREDNISOLONE; PROTON PUMP INHIBITOR;

ALGORITHM; ANAPHYLAXIS; ARTICLE; CLINICAL FEATURE; DEPRESSION; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EXTRACUTANEOUS MASTOCYTOMA; HUMAN; LOW DRUG DOSE; MAST CELL; MAST CELL LEUKEMIA; POINT MUTATION; SARCOMA; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS CLONAL HAEMATOLOGICAL NON MAST CELL LINEAGE DISEASE; TREATMENT RESPONSE; URTICARIA PIGMENTOSA;

EID: 79551623609     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794815293     Document Type: Article

References (28)

1. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112: 946-956.
2. Patnaik MM, Rindos M, Koudis PA, Tefferi A, Pardanani A. Systemic mastocytosis. a concise clinical and laboratory review. Arch Pathol Lab Med 2007; 131: 784-791.
3. Arinobu Y, Iwasaki H, Akashi K. Origin of basophils and mast cells. Allergol Int 2009; 58: 21-28.
4. Kaleshnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008; 9: 1215-1223.
5. Pardanani A, Akin C, Valent P. Pahogenesis, clinical features, and treatment advances in mastocytosis. Best Practice Res Clin Haematol 2006; 19: 595-619.
6. Orfao A, Escribano L, Villarrubia J, et al. Flow cytometric analysis of mast cells from normal and pathological uman bone marrow samples: identification and enumeration. Am J Pathol 1996; 149: 1493-1499.
7. Horny H-P, Akim C, Metcalfe DD, et al. In: Swerdlow SH, Campo E, Harris NL, et al., Eds. WHO classification of tumours of haematopoietic and lymphoid Tissues. Lyon: IARC 2008: pp. 54-63.
8. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of ckit product. J Clin Invest 1993; 92: 1736-1744.
9. Pagano L, Valentini CG, Caira M, et al. Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 2008; 88: 483-488.
10. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematologica 2005; 114: 26-40.
11. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717.
12. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635-641.
13. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996; 22: 501-505.
14. Schernthaner GH, Spanblochl E, Sperr WR, et al. Effects of α - interferon 2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 2000; 79: 660-666.
15. Kirshenbaum AS, Worobec AS, Davis TA, Goff JP, Semere T, Metcalfe DD. Inhibition of human mast cell growth and differentiation by interferon gamma-1b. Exp Hematol 1998; 26: 245-251.
16. Bergmann L, Mitrou PS. Recombinant gamma interferon in the treatment of a patient with malignant mastocytosis. Blut 1985; 51:218.
17. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol 1991; 85: 220.
18. Hubner C, Wedding U, Strater J, Limberg B, Stremmel W. Clinical stable systemic Mastocytosis with interferon alpha-2b therapy. J Intern Med 1997; 241: 529-533.
19. Reinacher-Schick A, Petrasch S, Longley BJ, Teschendorf C, Graeven U, Schmiegel W. Case report. C-kit mutation and osteopetrosis-like osteopathy in a patient with systemic mast cell disease. Ann Hematol 1998; 77: 131-134.
20. Takasaki Y, Tsukasaki K, Jubashi T, Tomonaga M, Kamihira S, Makiyama K. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon- α. Intern Med 1998; 37: 484-488.
21. Butterfield JH, Tefferi A, Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long term follow-up of a case. Leuk Res 2005, 29: 131-134.
22. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-2249.
23. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 2008; 142: 361-378.
24. Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center Experience. Am J Hematol 2004; 77: 209-214.
25. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-a: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119: 1090-1097.
26. Simon J, Lortholary O, Caillat-Vigneron N, et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol 2004; 52: 294-9.
27. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28: 249-257.
28. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006; 107: 1429-1439.